Systems and methods for ultrasonic bladder therapeutic agent delivery

By deploying catheters with expandable parts and ultrasound transducers in the urinary bladder and using ultrasound to form cavitation, the problem of urinary bladder barrier blocking therapeutic agent delivery is solved, improving the penetration and delivery of therapeutic agents Efficiency, enhances the effectiveness of ultrasound treatment and improves safety.

CN112261912BActive Publication Date: 2024-11-12VENSICA MEDICAL LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980035475.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-04-01
Filing Date
2019-04-01
Publication Date
2024-11-12
Estimated Expiration
2039-04-01

AI Technical Summary

Technical Problem

The prior art is difficult to effectively penetrate the barrier of the urinary bladder to deliver therapeutic agents into the bladder, and the ultrasonic cavitation mechanism needs to be close to the tissue surface and prevent cavitation bubbles from forming on the surface of the ultrasonic transducer to block ultrasonic waves.

Method used

A catheter consisting of an expandable portion and an ultrasound transducer was designed to increase the permeability of the bladder by deploying the catheter within the bladder and using ultrasound waves, while supplying therapeutic fluid through the fluid port and forming catheter within the bladder to Deliver therapeutic agents.

Benefits of technology

It improves penetration and delivery efficiency of therapeutic agents, protects the inner surface of the bladder from overtreatment, enhances the efficacy of ultrasound therapy, and is safer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112261912B_ABST
    Figure CN112261912B_ABST
Patent Text Reader

Abstract

The present invention discloses a catheter for ultrasound-driven bladder therapeutic agent delivery, comprising: a tube having a proximal expandable portion and a distal end; and at least one transducer sleeve accommodating at least one ultrasonic transducer mounted on the tube between the proximal expandable portion and the distal end.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 651,194, filed on April 1, 2018, entitled “SYSTEM AND METHOD FOR ULTRASONIC BLADDER THERAPEUTIC AGENT DELIVERY.”

[0003] This application is related to U.S. patent application No. 15 / 561,733, filed on September 26, 2017, entitled “ULTRASONIC URINARY BLADDER DRUG DELIVERY”.

[0004] The contents of the above-identified application are incorporated herein by reference as if fully set forth herein in their entirety. Technical Field

[0005] In some embodiments of the present invention, it is directed to catheters for bladder therapeutic agent delivery, and more particularly, but not exclusively, to ultrasound driven bladder therapeutic agent delivery. Background Art

[0006] Intravesical treatment of urinary bladder involves the inner surface of the bladder, which is covered by a transitional epithelial lining called the urothelium and glycosaminoglycan (GAG) units present on the urothelium. Both the urothelium and the GAG ​​units can serve as important barriers to toxins and waste present in urine, thereby making the bladder wall have low permeability properties. However, this compact and tight barrier may also limit the effective penetration of therapeutic agents delivered to the bladder during intravesical treatment. Some therapeutic molecules may not be able to penetrate the bladder barrier at all.

[0007] Ultrasound cavitation is a mechanism by which sound waves can increase the permeability of tissue. Cavitation bubbles collapse on tissue with high energy and open pores in the tissue, which results in increased permeability of the tissue to therapeutic agents.

[0008] The foregoing examples of the related art and limitations related thereto are intended to be illustrative and not exclusive. Other limitations of the related art will become apparent to those skilled in the art by reading the specification and studying the drawings. Summary of the invention

[0009] The following embodiments and aspects thereof are described and illustrated in conjunction with systems, tools, and methods, which are exemplary and illustrative, and not limiting in scope.

[0010] According to one aspect of some embodiments of the present invention, there is provided a catheter for ultrasound-driven bladder therapeutic agent delivery, the catheter comprising: a tube, two or more expandable portions mounted on the tube, one or more ultrasonic transducers mounted on the tube between the two or more expandable portions, and a transducer sleeve disposed between the two or more expandable portions and accommodating the one or more transducers. According to some embodiments, the transducer sleeve and the expandable portion comprise a single balloon. In some embodiments, the expandable portion comprises a stent.

[0011] According to some embodiments, the maximum cross-sectional area of ​​the transducer sleeve in the expanded state is smaller than the maximum cross-sectional area of ​​any of the expandable portions at least at its maximum circumference. According to some embodiments of the invention, at least one of the expandable portions is an ellipsoid, and at least one of the expandable portions and the tube are concentric. According to some embodiments of the invention, at least one of the expandable portions and the transducer are concentric.

[0012] According to some embodiments of the invention, the tube comprises at least one fluid port within the lumen of at least one of the expandable portions and / or at least one fluid port along its length leading to the lumen of the bladder. The ports are configured to supply the fluid into the lumen of the bladder and / or to withdraw fluid from the bladder.

[0013] According to some embodiments of the invention, the transducer is elevated from the surface of the tube so as to define a gap between the transducer and the surface of the tube. According to some embodiments of the invention, the maximum circumference of the transducer sleeve is less than 50% of the maximum circumference of at least one expandable portion, and / or the expansion pressure of the transducer sleeve is greater than the expansion pressure of the expandable portion. According to some embodiments of the invention, the tube includes one or more conduits for supplying a therapeutic fluid via the port. According to some embodiments of the invention, the tube includes one or more conduits for supplying an inflation fluid via the port. According to some embodiments of the invention, the tube includes one or more conduits for supplying a fluid via the port.

[0014] According to some embodiments of the invention, the transducer is configured to create cavitations in the inflation treatment fluid.

[0015] According to an aspect of some embodiments of the present invention, there is provided a catheter for ultrasound-driven bladder therapeutic agent delivery, the catheter comprising: a tube having a proximal portion and a distal end; a proximal expandable portion mounted on the proximal portion of the tube; one or more transducers mounted on the tube between the proximal expandable portion and the distal end; and a transducer sleeve accommodating one or more transducers between the proximal expandable portion and the distal end. In some embodiments, one or more of the expandable portions comprises a balloon.

[0016] According to some embodiments of the invention, the balloon is annular and / or configured to expand distally toward the distal end. According to some embodiments of the invention, the tube comprises at least one fluid port along its length, the fluid port leading to the lumen of the bladder and / or located between the transducer and the balloon. According to some embodiments of the invention, the port is configured to supply the fluid into the lumen of the bladder and / or to withdraw fluid from the bladder.

[0017] According to some embodiments of the invention, the maximum circumference of the transducer sleeve is less than 50% of the maximum circumference of the balloon. According to some embodiments, a volume is defined between the transducer and the transducer sleeve. According to some embodiments, an inflation pressure of the transducer sleeve is greater than an inflation pressure of the balloon. According to some embodiments of the invention, the tube includes one or more conduits for supplying a therapeutic fluid via the port.

[0018] According to an aspect of some embodiments of the present invention, there is provided a method for treating a bladder using a catheter for ultrasound-driven delivery of a bladder therapeutic agent, comprising: inserting a distal expandable portion of the catheter into the bladder via the urethra, expanding the expandable portion, supplying a therapeutic fluid into the bladder through at least one therapeutic fluid port in the catheter, advancing the catheter in the bladder and inserting a proximal expandable portion of the catheter into the bladder, expanding the proximal expandable portion and capturing the therapeutic fluid between the distal expandable portion and the proximal expandable portion, and applying ultrasound to form cavitation in the therapeutic fluid. In some embodiments, the method for treating a bladder using a catheter for ultrasound-driven delivery of a bladder therapeutic agent comprises, after ceasing to emit ultrasonic energy, supplying a therapeutic fluid into the bladder through at least one therapeutic fluid port in the catheter.

[0019] According to some embodiments of the invention, the method comprises supplying the therapeutic fluid through a port between the expandable portions. According to some embodiments of the invention, the therapeutic fluid is a gaseous therapeutic fluid.

[0020] According to an aspect of some embodiments of the present invention, there is provided a method for treating a bladder using a catheter for ultrasound-driven delivery of a bladder therapeutic agent, comprising: inserting a distal expandable portion of the catheter into the bladder via the urethra, expanding the expandable portion, supplying an inflation fluid into the bladder through at least one fluid port in the catheter, releasing ultrasonic energy and forming cavitation in the inflation fluid, discharging the bladder contents, supplying a therapeutic fluid into the bladder through at least one therapeutic fluid port in the catheter, and releasing ultrasonic energy and forming cavitation in the therapeutic fluid.

[0021] According to some embodiments of the invention, the method comprises emptying the bladder and flushing the bladder with saline before supplying the inflation fluid into the bladder.

[0022] According to some embodiments, the method comprises ceasing, during the expelling of the bladder contents, emitting ultrasonic energy and / or supplying the therapeutic fluid into the bladder through at least one therapeutic fluid port in the catheter.

[0023] According to an aspect of some embodiments of the present invention, there is provided a catheter for ultrasound-driven delivery of a bladder therapeutic agent, comprising: a tube having a proximal expandable portion and a distal end; and at least one transducer sleeve accommodating at least one ultrasonic transducer mounted on the tube between the proximal expandable portion and the distal end.

[0024] According to an aspect of some embodiments of the present invention, a catheter is provided, wherein at least one expandable portion is capable of expanding from a contracted state to an expanded state within a bladder, in which expanded state the expandable portion is pushed against the bladder wall to form a sealed volume within the bladder between the expandable portion and a trigone region of the bladder.

[0025] In some embodiments, the catheter comprises at least one additional expandable portion, wherein the transducer sleeve is disposed between the proximal expandable portion and the at least one additional expandable portion. In some embodiments, the transducer sleeve and at least one of the expandable portions are in fluid communication.

[0026] In some embodiments, the maximum cross-sectional area of ​​the transducer sleeve in the expanded state is less than the maximum cross-sectional area of ​​any of the expandable portions at least at its maximum circumference. In some embodiments, at least one of the expandable portions is an ellipsoid.

[0027] In some embodiments, at least one of the expandable portions and the tube are concentric. In some embodiments, at least one of the expandable portions and the transducer are concentric. In some embodiments, the tube comprises at least one fluid port located within a lumen of at least one of the expandable portions.

[0028] In some embodiments, the tube comprises at least two fluid ports in fluid communication with the lumen of the transducer sleeve, and wherein fluid flow is maintained between the ports. In some embodiments, the transducer is located between the ports.

[0029] In some embodiments, the tube comprises at least one therapeutic fluid port along its length that opens into the lumen of the bladder. In some embodiments, the catheter comprises a blind tip at the distal end, wherein the at least one therapeutic fluid port is located along the circumference of the tip. In some embodiments, the transducer is elevated from a surface of the tube so as to define a gap between the transducer and the surface of the tube.

[0030] In some embodiments, the catheter comprises at least one spacer positioned on the tube, and wherein the transducer is mounted on the at least one spacer. In some embodiments, the maximum circumference of the transducer sleeve is less than 50% of the maximum circumference of at least one expandable portion. In some embodiments, the tube comprises one or more conduits for supplying fluid via the treatment fluid port.

[0031] In some embodiments, at least one expandable portion is annular. In some embodiments, the at least one expandable portion is configured to expand distally toward the distal end. In some embodiments, the catheter includes at least one fluid port, the at least one fluid port being located between the transducer and the at least one expandable portion.

[0032] In some embodiments, in the expanded state, a volume is defined between the transducer and the transducer sleeve.

[0033] According to an aspect of some embodiments of the present invention, there is provided a method for treating a bladder using a catheter for ultrasound-driven delivery of a bladder therapeutic agent, comprising: inserting a distal expandable portion of the catheter into the bladder via the urethra, expanding the expandable portion, supplying a therapeutic fluid into the bladder through at least one therapeutic fluid port in the catheter, advancing the catheter in the bladder and inserting a proximal expandable portion of the catheter into the bladder, expanding the proximal expandable portion and capturing the therapeutic fluid between the distal expandable portion and the proximal expandable portion, and forming cavitation in the therapeutic fluid.

[0034] In some embodiments, the method includes supplying the therapeutic fluid through a port between the expandable portions. In some embodiments, the therapeutic fluid is a gaseous therapeutic fluid.

[0035] According to an aspect of some embodiments of the present invention, there is provided a method for treating a bladder using a catheter for ultrasound-driven delivery of a bladder therapeutic agent, comprising: inserting a distal expandable portion of the catheter into the bladder via the urethra, supplying a fluid into the bladder through at least one fluid port in the catheter, releasing ultrasonic energy and forming cavitation in the aerated fluid, draining the bladder contents, and supplying a therapeutic fluid into the bladder through at least one therapeutic fluid port in the catheter. In some embodiments, the fluid is aerated.

[0036] In some embodiments, the method includes expanding a distal expandable portion of the catheter prior to supplying a therapeutic fluid into the bladder. In some embodiments, the method includes emptying the bladder and flushing the bladder with saline prior to supplying the inflation fluid into the bladder.

[0037] In some embodiments, the method includes ceasing to emit ultrasonic energy and / or supply the therapeutic fluid into the bladder through at least one therapeutic fluid port in the catheter during the expelling of the bladder contents. In some embodiments, the method includes further advancing the proximal expandable portion before emitting ultrasonic energy. In some embodiments, the method includes expanding the proximal expandable portion before emitting ultrasonic energy. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Exemplary embodiments are shown in the accompanying drawings. Dimensions of components and features shown in the drawings are generally chosen for convenience and clarity of illustration and are not necessarily shown to scale. The drawings are listed below.

[0039] Figure 1A and Figure 1B (collectively, FIG. 1 ) is a simplified plan view illustration of a catheter for ultrasound-driven bladder therapeutic agent delivery according to some embodiments of the present invention and Figure 1A A simplified illustration of a perspective magnification of the circled area;

[0040] Figure 2 is a simplified illustration of a perspective view of a catheter for ultrasound-driven delivery of a bladder therapeutic agent according to some embodiments of the present invention;

[0041] Figure 3 is a simplified illustration of a perspective view of a catheter for ultrasound-driven delivery of a bladder therapeutic agent according to some embodiments of the present invention;

[0042] FIG. 4A to FIG. 4Dis a simplified plan view of a method of implementing a catheter for ultrasound driven treatment of the bladder according to some embodiments of the present invention;

[0043] Figure 5 is a flow chart of a method for deploying a catheter for ultrasound-driven treatment of a bladder wall according to some embodiments of the present invention;

[0044] FIG. 6A to FIG. 6E is a simplified plan view of a method of implementing a catheter for ultrasound driven treatment of the bladder according to some embodiments of the present invention;

[0045] Figure 7 is a flow chart of a method for deploying a catheter for ultrasound-driven treatment of a bladder wall according to some embodiments of the present invention;

[0046] Fig. 8A and Figure 8B (collectively, FIG. 8 ) is a simplified illustration of a plan view of a catheter for ultrasound-driven bladder therapeutic agent delivery according to some embodiments of the present invention and Fig. 8A A simplified illustration of a perspective magnification of the circled area in FIG.

[0047] Fig. 9 is a simplified illustration of a side view of a catheter for ultrasound driven delivery of a bladder therapeutic agent according to some embodiments of the present invention;

[0048] Fig.10 is a simplified illustration of a side view of a catheter for ultrasound driven delivery of a bladder therapeutic agent according to some embodiments of the present invention;

[0049] Fig.11 is a simplified illustration of a side view of a catheter for ultrasound driven delivery of a bladder therapeutic agent according to some embodiments of the present invention;

[0050] Fig.12 is a simplified illustration of a side view of a catheter for ultrasound driven delivery of a bladder therapeutic agent according to some embodiments of the present invention;

[0051] Fig.13 is a simplified illustration of a side view of a catheter for ultrasound driven delivery of a bladder therapeutic agent according to some embodiments of the present invention;

[0052] Fig.14 is a simplified illustration of a side view of a catheter for ultrasound driven delivery of a bladder therapeutic agent according to some embodiments of the present invention;

[0053] Fig.15 is an exemplary graph of parameters of an implementation of a catheter for ultrasound driven treatment of the bladder according to some embodiments of the present invention;

[0054] Fig.16is the detrusor contractility after each treatment (treatment using a catheter for ultrasound-driven treatment of the bladder) compared to untreated tissue, and the gold standard 100 units A graph comparing detrusor contractility following intravesical injection; and

[0055] Fig.17 is a table of efficacy data from two human patients comparing preoperative bladder function to bladder function 14 days postoperatively. DETAILED DESCRIPTION

[0056] Some challenges in the ultrasonic cavitation mechanism are that cavitation may need to be formed in the fluid close to the surface of the tissue to be treated to enhance the delivery of the therapeutic agent. In addition, it is necessary to prevent cavitation bubbles from forming on or near the surface of the ultrasonic transducer, thereby blocking the ultrasonic waves.

[0057] According to an aspect of some embodiments of the present invention, a catheter for ultrasound-driven bladder therapeutic agent delivery is provided. In some embodiments, the catheter comprises a tube, one or more transducers mounted on the tube, at least one expandable portion and a transducer sleeve. In some embodiments, the transducer sleeve is configured to enclose one or more transducers, wherein a volume is defined between the enclosed transducer and the wall of the transducer sleeve. In some embodiments, the transducer sleeve is disposed between at least two expandable portions. In some embodiments, the transducer sleeve interconnects at least two expandable portions.

[0058] According to some embodiments of the invention, the tube comprises at least one fluid port configured to supply fluid to or remove fluid from at least one of the at least one expandable portion. In some embodiments, the expandable portion is expanded by fluid supplied to the portion via the fluid port. In some embodiments, the transducer sleeve is expandable.

[0059] According to some embodiments of the invention, the tube includes at least one therapeutic fluid port configured to supply a therapeutic fluid into the bladder. In some embodiments, the tube includes at least one therapeutic fluid port at a distal end of the tube. In some embodiments, the tube includes at least one therapeutic fluid port between the transducer sleeve and either of the expandable portions. In some embodiments, the tube includes at least one therapeutic fluid port between the transducer sleeve and a proximal expandable portion. As used herein, the term "proximal" refers to close to an operator and away from a subject being treated, and the term "distal" refers to away from an operator and toward a subject being treated. In some embodiments, fluid may be removed via the therapeutic fluid port.

[0060] In some embodiments, the at least one expandable portion in the expanded state is shaped as a sphere or an ellipsoid. In some embodiments, the at least one expandable portion in the expanded state is annular. In some embodiments, the at least one expandable portion in the expanded state comprises a C-shaped cross-section. In some embodiments, the at least one expandable portion in the expanded state comprises an umbrella-like configuration. In some embodiments, the catheter comprises an expandable portion shaped as a "dog bone" in the expanded state, having two expansion portions interconnected by a transducer sleeve.

[0061] In some embodiments, the at least one expandable portion is configured to keep at least a portion of the internal bladder surface away from the transducer sleeve. In some embodiments, the transducer sleeve defines an inner cavity and the catheter passes through the inner cavity. In some embodiments, one or more transducers are mounted on the portion of the catheter within the transducer sleeve tube inner cavity. In some embodiments, the transducer is surrounded by a fluid that occupies a volume defined between the transducer and the transducer sleeve surrounding the transducer. In some embodiments of the present invention, the fluid cools the enclosed transducer. In some embodiments, the fluid is an acoustic fluid for effectively delivering the sound waves generated by the transducer.

[0062] According to some embodiments, the transducer sleeve in the expanded state is cylindrical. In some embodiments, at any point along its longitudinal axis, the maximum cross-sectional area of ​​the transducer sleeve in the expanded state is less than the maximum cross-sectional area of ​​any of the expandable portions in the expanded state. In some embodiments, at any point along its longitudinal axis, the maximum cross-sectional area of ​​the transducer sleeve in the expanded state is two-thirds of the maximum cross-sectional area of ​​the expandable portion in the expanded state. In some embodiments, at any point along its longitudinal axis, the maximum cross-sectional area of ​​the transducer sleeve in the expanded state is one-third of the maximum cross-sectional area of ​​the expandable portion in the expanded state. According to some embodiments, the tube, at least one expandable portion, and the transducer sleeve are concentric.

[0063] According to some embodiments of the present invention, the expandable portion is configured to occupy a portion of the bladder volume in the expanded state while defining a treatment volume defined by the walls of the transducer sleeve, the walls of the expandable portion being disposed at each end of the transducer sleeve and at the bladder wall. In some embodiments, in the expanded state, the expandable portion occupies at least half of the bladder volume. In some embodiments, when the bladder is in the expanded state, the expandable portion occupies between one-third and two-thirds of the bladder volume. This configuration directs fluid containing a therapeutic agent in the bladder into the treatment volume near the transducer while protecting sensitive areas of the bladder at the inner surface of the bladder (e.g., the trigone) from treatment with the therapeutic agent and / or energy transmitted by the transducer. In some embodiments of the present invention, at least some of the expandable portions are configured to apply pressure on the inner surface of the bladder in the expanded state.

[0064] According to some embodiments of the invention, at least one of the expandable portions is configured to engage the bladder wall in an expanded state and prevent fluid from draining from the treatment volume between the expandable portion and the bladder wall. In some embodiments, the expandable portion in the expanded state maintains the tube concentric with the bladder wall.

[0065] According to some embodiments of the invention, the expandable portion and the transducer sleeve are parts of the same balloon mounted on the tube. In some embodiments, the transducer sleeve is inelastic and has a fixed expansion size. In some embodiments, the transducer sleeve is rigid or includes a reinforcing element.

[0066] According to some embodiments of the invention, the catheter comprises a gap between the transducer and the tube. In some embodiments, the gap is in the range of 0.05 mm to 4 mm. According to some embodiments, the gap is in the range of 0.1 mm to 2.5 mm. In some embodiments, the transducer is connected to the tube via a spacer.

[0067] According to an aspect of some embodiments of the present invention, there is provided a catheter for ultrasound-driven delivery of a bladder therapeutic agent. The catheter comprises a tube, a proximal expandable portion, one or more transducers mounted on the tube between the proximal expandable portion and the distal end of the tube, and a transducer sleeve enclosing one or more of the transducers. In some embodiments, the transducer sleeve has a deflated state and an expanded state.

[0068] In some embodiments, the proximal expandable portion and the transducer sleeve comprise different balloons. In some embodiments, the proximal expandable portion and the transducer sleeve comprise portions of one balloon. In some embodiments, the proximal expandable portion in the expanded state is shaped as a sphere or an ellipsoid. In some embodiments, the proximal expandable portion in the expanded state is shaped as an annular body. In some embodiments, at least one of the proximal expandable portions in the expanded state comprises a C-shaped cross-section. In some embodiments, at least the proximal expandable portion in the expanded state comprises an umbrella-like configuration.

[0069] According to some embodiments of the invention, the tube comprises at least one treatment fluid port configured to supply treatment fluid into the bladder. In some embodiments, the treatment fluid port is located between the transducer sleeve and the proximal expandable portion. In some embodiments, fluid can be removed via the treatment fluid port.

[0070] According to some embodiments, the proximal expandable portion includes a balloon that, in an expanded state, maintains the tube at a predetermined position within the bladder. In some embodiments, the proximal expandable portion is configured to engage the bladder wall in an expanded state and prevent fluid from draining from a treatment volume within the bladder to between the proximal expandable portion wall and the bladder wall.

[0071] According to some embodiments of the present invention, the transducer sleeve in the expanded state is cylindrical and has a uniform cross-section at least at a portion of its length. In some embodiments, at any point along its longitudinal axis, the maximum cross-sectional area of ​​the transducer sleeve in the expanded state is less than the maximum cross-sectional area of ​​the proximal expandable portion in the expanded state. In some embodiments, at any point along its longitudinal axis, the maximum cross-sectional area of ​​the transducer sleeve in the expanded state is two-thirds of the maximum cross-sectional area of ​​the proximal expandable portion in the expanded state. In some embodiments, at any point along its longitudinal axis, the maximum cross-sectional area of ​​the transducer sleeve in the expanded state is less than 50% of the maximum cross-sectional area of ​​the proximal expandable portion in the expanded state. According to some embodiments, the tube, the proximal expandable portion and the transducer sleeve are concentric.

[0072] According to some embodiments of the invention, the transducer sleeve in the expanded state does not intersect an imaginary cone extending between a vertex located at the distal end of the tube and a plane defined by the circumference of the expandable portion in the expanded state. According to some embodiments of the invention, the transducer sleeve is inelastic and has a limited expansion dimension. In some embodiments, the transducer sleeve is rigid or includes a reinforcing element.

[0073] In some embodiments, the therapeutic fluid can be an un-aerated fluid. However, in some embodiments, the amount of cavitation bubbles generated in the therapeutic fluid is increased by providing an aerated therapeutic fluid. Therefore, according to one aspect of some embodiments of the present invention, a method for increasing the amount of cavitation bubbles in a therapeutic agent used with a catheter for ultrasonically driven bladder therapeutic agent delivery is provided. In some embodiments, the method includes pressurizing a sterile liquid with a gas and generating an "aerated liquid". In some embodiments, the method includes releasing a therapeutic agent into the aerated liquid and forming an aerated therapeutic fluid. In some embodiments, the method includes inserting an aerated therapeutic fluid into the bladder via a catheter for ultrasonically driven bladder therapeutic agent delivery, and forming cavitation in the therapeutic fluid. According to some embodiments of the present invention, the method includes, for example, pressurizing a sterile liquid with a gas, including pressurizing at a pressure of about 8 to 30 atmospheres and continuing for a predetermined duration.

[0074] In some embodiments, the therapeutic agent fluid is mixed with the unaerated fluid but not the aerated fluid.

[0075] In some embodiments, the catheter comprises an expandable portion, such as a balloon, a stent, or any combination thereof. In some embodiments, at least one expandable portion comprises a stent.

[0076] Reference now Figure 1A and Figure 1B (collectively referred to as FIG. 1 ), which are simplified illustrations of side views and perspective magnified views of a catheter for ultrasound-driven bladder therapeutic agent delivery according to some embodiments of the present invention. As shown in FIG. 1 , the catheter 10 includes a tube 11, a transducer 30 mounted on the tube 11, and an expandable portion 20 mounted on the tube 11 and enclosing the transducer 30. In the exemplary embodiment depicted in FIG. 1 , the expandable portion 20 is a balloon. In some embodiments, the expandable portion 20 includes two expandable portions 24 and 26, which are coupled to and clamp a transducer sleeve 22 disposed therebetween. The tube 11 includes at least one fluid port 14 and 15, which is configured to supply at least one of the portions 22, 24, and 26 of the balloon 20 or remove fluid therefrom. The transducer sleeve 22 encapsulates the transducer 30 and defines a volume between the transducer sleeve 22 and the wall of the transducer.

[0077] In some embodiments, the tube includes one or more conduits, or in other words, a fluid supply channel (not shown) supplies fluid from a fluid source to one or more ports. As used herein, the terms "conduit" and "fluid supply channel" are interchangeable. One or more fluid supply channels are disposed inside the tube or along the outer surface of the tube. In some embodiments, a fluid flow is generated within the balloon 20 and at least in the internal volume of the transducer sleeve 22 by providing fluid via a fluid port (e.g., port 14) and removing fluid via another fluid port (e.g., port 15).

[0078] In some embodiments, the fluid provided to the balloon includes an acoustic fluid. As cited herein, the term "acoustic fluid" refers to a fluid with a high cavitation energy threshold to prevent the formation of cavitation bubbles that interfere with sound waves in the liquid during ultrasonic operation, and to prevent damage to the catheter. Acoustic fluid allows efficient propagation of ultrasonic energy. One aspect of this fluid is that it reduces cavitation, which can prevent ultrasonic energy from propagating from the transducer to the inner surface of the bladder. This fluid can be a degassed fluid, such as a degassed solution (such as a boiling saline solution, or a solution whose gas content is filtered out). The acoustic fluid helps to transmit the sound waves generated by the transducer 30 to the treatment fluid surrounding the transducer sleeve through the surface of the transducer sleeve 22. The acoustic fluid can also cool the enclosed transducer 30, for example, by thermal convection. By cooling the transducer, the transducer can operate under the desired parameters for a longer treatment time. In addition, overheating of the bladder tissue caused by the heated transducer is avoided.

[0079] The acoustic fluid provided to the transducer sleeve 22 does not contain bubbles to serve as nucleation seeds for generating cavitation, and thus isolates the cavitation phenomenon from the transducer 30 and moves it toward the bladder wall. Ultrasonic waves travel from the transducer through the acoustic fluid without generating cavitation, and therefore travel freely through this medium toward the surface of the sleeve 22. The waves then travel toward the bladder tissue through the therapeutic fluid in the treatment volume between the sleeve and the bladder. Cavitation is generated in the treatment fluid, thereby resulting in the delivery of the therapeutic agent into the bladder. In this way, the transducer can be placed farther away from the inner surface of the bladder than a transducer exposed to the treatment fluid inside the bladder. The generation of cavitation increases the efficacy of ultrasound therapy, as described in detail in U.S. Patent Application No. 15 / 561,733, issued to the same inventor.

[0080] As shown in the exemplary embodiment depicted in FIG. 1 and in view A of FIG. 1 , tube 11 includes a tip 16 that includes a plurality of fluid ports 17. In some embodiments, tip 16 is convex and is configured to allow easy insertion of the catheter into the bladder and to reduce accidental damage to the inner surface of the bladder during deployment of the catheter within the bladder. In some embodiments, tip 16 has a rectangular geometry with a fluid port at the distal end of the tip. In some embodiments, tip 16 has no ports. For example, bladder fluid ports 17 can be used for one or more of the following functions: inserting a therapeutic fluid into the bladder, removing a therapeutic fluid from the bladder, inserting a tissue cleaning fluid (such as saline) to remove the therapeutic fluid, and removing fluid from the bladder (e.g., urine that fills the bladder before treatment).

[0081] In some embodiments, the shape of tip 16 is one of an annular body, a donut shape, a disc shape, a sphere and a hemisphere. In some embodiments, tip 16 is rigid or semi-rigid. In some embodiments, (one or more) ports 17 are distributed along at least a portion of the circumference of tip 16. In some embodiments, tip 16 includes a surface 40 positioned distally relative to (one or more) ports 17. In some embodiments, surface 40 is circular. In some embodiments, tip 16 is blind-ended. In some embodiments, the fluid flowing in tube 11 leaves (one or more) ports 17.

[0082] A potential advantage of multiple openings (ports) is that multiple ports provide redundancy in the event of port clogging when inserting or removing fluids. In some embodiments, the transducer sleeve and the expandable portion are disposed on different balloons, and at least one treatment fluid port may be disposed at the tube between the transducer sleeve and the expandable portion. In some embodiments, at least one treatment fluid port may be disposed at the tube at a proximal tube portion that is not covered by any expandable portion.

[0083] In some embodiments, the fluid port(s) 17 are positioned radially around the longitudinal axis of the catheter and / or tube. In some embodiments, the fluid port(s) 17 are positioned such that fluid flowing out of the fluid port(s) 17 is ejected at a non-zero angle relative to the longitudinal axis of the catheter and / or tube.

[0084] For example, in the exemplary embodiment depicted in FIG. 1 and view A of FIG. 1 , when the catheter 10 is inserted into the bladder so that the tip 16 is pushed against the bladder wall (e.g., the surface opposite the trigone), i.e., the marked area 5″, or other portions of the urinary tract bladder wall, the bladder wall does not block the fluid port(s) 17.

[0085] In some embodiments, tip 16 comprises a distal opening of distal portion 11b of tube 11. In some embodiments, tip 16 comprises at least one port 17 at surface 40. In some embodiments, tip 16 comprises a covering comprising at least one aperture, such as a mesh. In some embodiments, the covering of tip 16 is rigid or semi-rigid. In some embodiments, the covering defines a volume around tip 16.

[0086] For example, in some embodiments, when the catheter 10 is inserted into the bladder so that the covering of the tip 16 is pushed against the bladder wall, such as the distal portion of the bladder (such as the surface opposite the trigone), i.e., the marked area 5", or other portions of the urinary tract bladder wall, the bladder wall does not block at least one orifice of the covering of the tip 16.

[0087] In some embodiments, at least one of the transducers, at least one of the expandable portions, and the tube are concentric. In some embodiments, at least two expandable portions are concentric. In some embodiments, the transducer and at least one expandable portion are concentric. In some embodiments, the transducer sleeve and at least one expandable portion are concentric. In some embodiments, the transducer sleeve and the transducer are concentric.

[0088] An advantage of the concentric position of the catheter, expandable portion, transducer sleeve, and / or transducer is that the catheter maintains an equal distance between the inner bladder wall and the transducer so that the treated portions of the bladder wall can receive the same or nearly equal treatment. Additionally, in some embodiments, the treated portions of the bladder wall can receive a predetermined variation of treatment.

[0089] In some embodiments, tube 11 includes one or more conduits that supply fluid to one or more of ports 14 / 15 / 17. In some embodiments, each conduit leads to a specific port 14 / 15 / 17. In some embodiments, each conduit leads to a separate port 14 / 15 / 17. In some embodiments, a conduit leads to at least one of ports 14 / 15 / 17.

[0090] In some embodiments, the tube lumen 11 includes at least one conduit. In some embodiments, the at least one conduit is in fluid communication with the proximal opening 34 / 36 / 38 of the catheter 10.

[0091] In some embodiments, the catheter 10 includes at least one proximal opening 34 / 36 / 18 through which fluid enters and / or leaves one or more ports 14 / 15 / 17. In some embodiments, the proximal opening 34 / 36 / 38 is in fluid communication with a reservoir for fluids, such as a therapeutic fluid, a fluid (e.g., saline), an inflation fluid, and an acoustic fluid. In some embodiments, the proximal opening 34 / 36 / 38 is in fluid communication with a drain bag. In some embodiments, at least one catheter is coupled to one or more proximal openings 34 / 36 / 38. In some embodiments, each of the proximal openings 34 / 36 / 38 is in fluid communication with at least one of the ports 14 / 15 / 17.

[0092] Figure 2 is a simplified perspective illustration of an implementation of ultrasound driven bladder therapeutic agent delivery within bladder 1 according to some embodiments of the present invention. Figure 2 In the exemplary embodiment depicted in FIG, the geometry of the expandable portions 24 and 26 is an ellipsoid and is in an expanded state. In some embodiments, the expandable ellipsoidal portions 24 and 26 both occupy a portion of the bladder volume, thereby forming a treatment volume 7 around the transducer sleeve 22 between the expandable ellipsoidal portions 24 and 26 and the bladder wall 5. A potential advantage of this configuration is that the therapeutic agent disposed in the bladder 1 will be directed into the treatment volume 7 between the transducer 30 and the bladder wall 5, thereby limiting the treatment of the bladder tissue to the segment 5' of the bladder wall and the treatment volume 7 and benefiting from the full effect of the cavitation formed by the transducer 30. In addition, in some embodiments, this configuration introduces the fluid containing the therapeutic agent within the bladder 1 into the treatment volume 7 while protecting areas at the inner surface of the bladder 1 (e.g., the trigone) from being treated by the therapeutic agent and / or the energy transmitted by the transducer 30. In some embodiments, in the expanded state, the expandable portions 24 and 26 occupy 30% to 70% of the bladder volume. In some embodiments, in the expanded state, the expandable portions 24 and 26 occupy 40% to 60% of the bladder volume.

[0093] Typically, in a relaxed state, the shape of the bladder wall is wavy. In some embodiments, the inflated balloon 20 applies tension in the inner surface 5 of the bladder 1 in multiple directions, thereby straightening at least a portion of the bladder wall of the bladder in at least a region 5' that interfaces with the treatment volume 7 between the expandable portions 24 and 26, such as Figure 2 shown.

[0094] Because the expanded balloon has a predictable geometry and size at a predefined pressure, the measurement of the treatment volume 7 around the transducer 30 is also predictable. The expandable portions 24 and 26 can be designed to have a circumference in the fully expanded state that will define a predetermined distance L1 between the transducer 30 and the treated surface 5' of the bladder. In some embodiments, uniform treatment can be achieved by making the treated tissue equidistant from the transducer. In some embodiments, the concentration of the therapeutic agent within the treatment fluid is determined by the predictable treatment volume 7. Straightening and stretching the bladder tissue can contribute to the efficacy of the treatment by increasing the permeability of the therapeutic agent into the bladder tissue. In addition, this structural configuration stabilizes the bladder wall and increases the safety of the procedure by preventing the bladder wall from collapsing onto or near the hot transducer surface. In addition, the transducer sleeve 22 prevents direct contact between the bladder and the transducer 30.

[0095] In some embodiments, and as described in greater detail elsewhere herein, one or more of the expandable portions is a stent.

[0096] In some embodiments, such as in the treatment of urobladder, the procedure is performed when the bladder is positioned vertically or nearly vertically, wherein the trigone is the lowest part of the urobladder. Figure 2 As shown, the distal expandable portion 26 does not seal the distal portion of the bladder (e.g., the surface opposite the trigone), i.e., the marked area 5'. The therapeutic fluid provided through the port 17 can then flow into the volume 7, for example, by gravity or a pressure gradient. In some embodiments, as Figure 2 As shown, the proximal expandable portion 24 engages the proximal surface of the bladder. In the expanded state, the expandable portion 24 can prevent fluid from being discharged from the treatment volume 7 pressed against the bladder wall. The expandable portion 24 can be pressed against and sealed against the proximal surface of the bladder (e.g., by static forces, such as gravity, fluid pressure, the distal ellipsoid pressing against the distal bladder surface). Therefore, during treatment, the treatment fluid is retained in the treatment volume 7, while the bladder tissue located outside the expandable portion 24 is protected from being exposed to the treatment fluid and acoustic energy and being treated.

[0097] In some embodiments, the proximal and / or distal expandable portions 24 / 26 shield portions of the bladder wall from ultrasonic energy. In some embodiments, the proximal expandable portion 24 shields the trigone of the bladder from ultrasonic energy. In some embodiments, the proximal and / or distal expandable portions 24 / 26 act as a container for a cooling fluid flow that increases heat dissipation from the transducer.

[0098] In some embodiments, at least one of the proximal and / or distal expandable portions 24 / 26 is filled with a fluid that has a high acoustic impedance and is therefore unable to conduct ultrasonic energy. In some embodiments, a non-conductive fluid inflates at least one of the proximal and / or distal expandable portions 24 / 26. In some embodiments, the non-conductive fluid prevents ultrasonic energy from being transmitted to untreated areas of the bladder (e.g., the trigone).

[0099] A potential advantage of having a non-conductive fluid within one or more of the expandable portions 24 / 26 is that ultrasound energy will not be transmitted to untreated portions of the bladder.

[0100] In some embodiments of the invention, expandable portion 24 acts as a catheter support and secures the position of tube 11 within bladder 1. In some embodiments, fluid within one or more expansion portions engaging inner surface 5 of bladder 1 cools the bladder by heat transfer between the bladder wall and the fluid.

[0101] In some embodiments, the volume and / or shape of the expandable portion 24 / 26 determines the distance between the treated surface 5' of the bladder and the transducer 30. In some embodiments, the volume and / or shape of the expandable portion 24 / 26 determines the distance between the treated surface 5' of the bladder and the transducer sleeve 22. In some embodiments, the distance between the treated surface 5' of the bladder and the transducer 30 and / or transducer sleeve 22 is predetermined.

[0102] The temperature of the treated surface 5' of the bladder is related to the heat dissipated by the transducer. Therefore, increasing the distance between the transducer 30 and the treated surface 5' of the bladder prevents overheating of the treated surface 5' of the bladder. In some embodiments, increasing the distance between the transducer 30 and the treated surface 5' of the bladder allows the transducer 30 to be heated to a higher temperature, for example by increasing the duration and / or frequency of the energy emitted by the transducer.

[0103] In some embodiments, increasing the frequency emitted by the transducer increases the therapeutic efficacy by increasing cavitation within the therapeutic fluid (and / or a combination of the inflation fluid and the therapeutic fluid). In some embodiments, increasing the on-time of the transducer increases the therapeutic efficacy by increasing cavitation within the therapeutic fluid (and / or a combination of the inflation fluid and the therapeutic fluid).

[0104] like Figure 3As shown, according to some embodiments of the present invention, the expandable portions 24 and 26 define a cylinder 23 between them, the wall of which is outlined by a dotted line, which coincides with the maximum circumference of the expandable portions 24 / 26 at Y1 and Y2, respectively. In some embodiments, and as explained in detail elsewhere herein, the maximum cross-sectional area of ​​the transducer sleeve 22 taken at Y3 is less than the maximum cross-sectional area of ​​the expansion portions 24 and 26. In some embodiments, in the expanded state, the diameter D10 of the expandable portions 24 and 26 is between 20 mm and 40 mm. In some embodiments, in the expanded state, the diameter D10 of the expandable portions 24 and 26 is between 20 and 40 mm. In some embodiments, the diameter D20 of the transducer sleeve 22 is between 5 mm and 15 mm. In some embodiments, the diameter D20 of the transducer sleeve 22 is between 6 mm and 12 mm. In some embodiments, the diameter D20 of the transducer sleeve 22 is between 8 mm and 10 mm. In some embodiments, in the expanded state, the length L30 of the transducer sleeve is between 5 and 25 mm. In some embodiments, in the expanded state, the length L30 of the transducer sleeve is between 10 and 15 mm.

[0105] In some embodiments, the transducer sleeve in the expanded state is cylindrical and has a uniform cross-section at least over a portion of its length. In some embodiments, at any point along its longitudinal axis, the maximum cross-sectional area of ​​the transducer sleeve in the expanded state is less than the maximum cross-sectional area of ​​the proximal expandable portion in the expanded state. In some embodiments, at any point along its longitudinal axis, the maximum cross-sectional area of ​​the transducer sleeve in the expanded state is two-thirds of the maximum cross-sectional area of ​​the proximal expandable portion in the expanded state. In some embodiments, at any point along its longitudinal axis, the maximum cross-sectional area of ​​the transducer sleeve in the expanded state is less than 50% of the maximum cross-sectional area of ​​the proximal expandable portion in the expanded state. According to some embodiments, the tube, the proximal expandable portion, and the transducer sleeve are concentric.

[0106] In some embodiments, the length of transducer 30 is 3-20 mm. In some embodiments, the length of transducer 30 is 4-14 mm. In some embodiments, the length of transducer 30 is 5-10 mm. In some embodiments, the length of transducer 30 is 6 mm.

[0107] In some embodiments, the width of transducer 30 is 3-14 mm. In some embodiments, the width of transducer 30 is 3-7 mm. In some embodiments, the width of transducer 30 is 3-5 mm. In some embodiments, the width of transducer 30 is 4 mm.

[0108] In some embodiments, the thickness of transducer 30 is 10-40 mm. In some embodiments, the thickness of transducer 30 is 15-30 mm. In some embodiments, the thickness of transducer 30 is 15-23 mm. In some embodiments, the thickness of transducer 30 is 20 mm.

[0109] In some embodiments, the balloon wall includes regions of variable elasticity, such that, for example, only portions of the balloon wall are elastically expandable. For example, diametrically opposed faces 24a and 24c (FIG. 1) of expandable portion 24 may be made inelastic, while face 24b along the circumference of expandable portion 24 is elastically flexible, so that expansion of portion 24 will be a greater radial expansion along tube 11 of the catheter.

[0110] In some embodiments, at least one of the expandable portions in the expanded state is shaped as at least one of a sphere, an ellipsoid, and a toroid. In some embodiments, at least one of the expandable portions in the expanded state comprises a C-shaped cross-section. In some embodiments, at least one of the expandable portions in the expanded state comprises an umbrella-like configuration.

[0111] In some embodiments, the transducer sleeve in the expanded state is cylindrical. In some embodiments, at any point along its longitudinal axis, the maximum cross-sectional area of ​​the transducer sleeve in the expanded state is less than the maximum cross-sectional area of ​​any of the expandable portions in the expanded state. In some embodiments, at any point along its longitudinal axis, the maximum cross-sectional area of ​​the transducer sleeve in the expanded state is two-thirds of the maximum cross-sectional area of ​​the expandable portion in the expanded state. In some embodiments, at any point along its longitudinal axis, the maximum cross-sectional area of ​​the transducer sleeve in the expanded state is one-third of the maximum cross-sectional area of ​​the expandable portion in the expanded state. In some embodiments, the tube, at least one of the expandable portions, and the transducer sleeve are concentric.

[0112] In some embodiments of the present invention, the expandable portion is configured to occupy a portion of the bladder volume in the expanded state while defining a treatment volume defined by the walls of the transducer sleeve, the walls of the expandable portion being disposed at each end of the transducer sleeve and the bladder wall. In some embodiments, in the expanded state, the expandable portion occupies at least half of the bladder volume. In some embodiments, when the bladder is in the expanded state, the expandable portion occupies between one-third and two-thirds of the bladder volume. This configuration directs fluid containing a therapeutic agent in the bladder into the treatment volume near the transducer while protecting sensitive areas of the bladder at the inner surface of the bladder (e.g., the trigone) from being treated with the therapeutic agent and / or being affected by energy transmitted by the transducer. In some embodiments of the present invention, at least some of the expandable portions are configured to apply pressure on the inner surface of the bladder in the expanded state.

[0113] In some embodiments, shaping of any balloon may be accomplished by molding, thickness differences, varying materials, integral components, etc. Another method for shaping any balloon portion may be to limit its expansion by an external component such as a sleeve or mesh.

[0114] In some embodiments, tube 11 has a uniform cross-section throughout its length. In some embodiments, the diameter of distal portion 11b of tube 11 is smaller than the diameter of proximal portion 11a of tube 11. In some embodiments, as shown in view A in FIG. 1, portion 11b includes distal tip 16. In some embodiments, portion 11b is connected to tube 11 below the proximal edge of transducer 30. In some embodiments, transducer 30 is mounted on portion 11b of tube 11 so that the outer surface of transducer 30 is positioned flush with proximal portion 11a of tube 11. In some embodiments, portion 11b includes a narrow tube portion inserted into tube 11.

[0115] In some embodiments, each of the ports 14 / 15 is supplied by a different fluid supply channel, such that supplying fluid to the expandable portion 26 via port 15 does not necessarily expand the expandable portion 24, and vice versa, even if the expandable portions 24 / 26 are in fluid communication via the transducer sleeve 22. In some embodiments, port 15 is associated with a different fluid supply channel of the tube 11. In some embodiments, port 14 is configured to be closed when fluid is supplied through port 15. A potential advantage of the configuration of ports 14 / 15 is that during deployment, the expandable portion 26 is configured to expand while the expandable portion 24 is still within the urethra 3, i.e., without expanding the expandable portion within the urethra 3 (which may be painful for the subject being treated).

[0116] Reference now FIG. 4A to FIG. 4D , which are simplified plan views of implementation methods of a catheter for ultrasound-driven treatment of the bladder. As shown in Figures 4a to 4d, the catheter for ultrasound-driven treatment of the bladder is deployed by the following method:

[0117] The catheter 10 is inserted through the urethra 3 (eg Figure 4A shown) in bladder 1;

[0118] The balloon 20 including the expandable portions 24, 26 and the transducer sleeve 22 is expanded by pressurized acoustic fluid (e.g., 20cc-40cc of fluid) ( Figure 4B ) to a predetermined pressure or volume, and maintaining the expansion portion 24 / 26 and the transducer sleeve 22 in the expanded state;

[0119] draining fluid from the bladder 1 through the therapeutic fluid port(s) 17;

[0120] supplying saline via therapeutic fluid port(s) 17;

[0121] As described elsewhere herein, mixing the therapeutic fluid with the inflation liquid (this step may be performed at any time before or during deployment of the catheter); and

[0122] The bladder is supplied with ( Figure 4C ) Treatment fluid (eg, 20-40 cc). In some embodiments, such as depicted by arrow 400, treatment fluid is supplied to the bladder lumen via treatment fluid port(s) 17.

[0123] Reference now Figure 5 , which is a flow chart of a method for deploying a catheter for ultrasound-driven treatment of the bladder wall according to some embodiments of the present invention; and reference is made to the corresponding FIG. 6A to FIG. 6E , which are simplified side views of a method for implementing a catheter for ultrasound-driven treatment of the bladder. Figure 5 As shown, the catheter 10 for ultrasound-driven treatment of the bladder 1 is deployed by the following method:

[0124] At step 1000, the distal expandable portion 26 of the catheter 10 is inserted into the bladder 1 through the urethra 3;

[0125] At step 1010, urine is removed from the bladder via port(s) 17;

[0126] At step 1020 , portion 26 is expanded to an expanded state by providing fluid into portion 26 via port 15 ;

[0127] Optionally, at step 1030, a therapeutic fluid is mixed with an inflation liquid as described elsewhere herein (this step may be performed at any time before or during deployment of the catheter);

[0128] At step 1040, supplying therapeutic fluid through the therapeutic fluid port(s) 17;

[0129] At step 1050, the proximal expandable portion 24 is further advanced through the urethra 3 into the bladder 1; and

[0130] At step 1060 , the proximal expandable portion 24 is expanded to the expanded state by providing fluid via the port 14 .

[0131] In some embodiments, the method includes expanding the proximal expandable portion, and capturing a therapeutic fluid between the distal expandable portion and the proximal expandable portion.

[0132] A potential advantage of using the method for deploying the ultrasonically driven catheter 10 is that the majority of the therapeutic fluid will not remain trapped within the distal volume between the distal expandable portion 26 and the bladder wall 5" opposite the trigone.

[0133] Fig. 6A is a simplified plan view illustration of the insertion of the distal expandable portion 26 into the bladder 1 through the urethra 3. In some embodiments, the proximal expandable portion 24 remains within the urethra 3.

[0134] Figure 6B 6 is a simplified plan view illustration of expanding the distal expandable portion 26 to an expanded state by providing fluid into the distal expandable portion 26 via the fluid port 15 (e.g., as depicted by arrow 600). In some embodiments, the distal expandable portion 26 and the proximal expandable portion 24 are in fluid communication. The fluid remains in the distal expandable portion 26, and the flow in the direction of the proximal expandable portion 24 is offset by the external pressure applied to the proximal expandable portion 24 by the urethral wall. Therefore, the proximal expandable portion 24 remains contracted within the urethra due to the pressure applied to the proximal expandable portion 24 by the urethral wall. In some embodiments, the proximal expandable portion 24 remains mostly contracted in the urethra.

[0135] Figure 6C is a simplified plan view illustration of supplying a therapeutic fluid through the therapeutic fluid port(s) 17. In some embodiments, the method includes supplying a therapeutic fluid through the therapeutic port(s) 17 into the volume 46 defined by the distal extension 26 and the bladder wall (e.g., as indicated by arrow 602).

[0136] Fig.6Dis a simplified plan view illustration of the proximal portion 24 being further advanced into the bladder 1 through the urethra 3. In some embodiments, during the further advancement of the proximal portion 24 into the bladder 1, the proximal portion 24 is not subject to external pressure exerted thereon by the urethra wall, and at least a portion of the fluid within the distal expandable portion 26 flows into the proximal expandable portion 24 to equalize the pressure within the expandable portions 24 and 26 according to LaPlace's law. In some embodiments, the fluid within the distal expandable portion 26 flows into the portion of the proximal expandable portion 24 that is within the bladder 1. In some embodiments, the volume of the distal expandable portion 26 is reduced due to the flow of fluid entering the proximal expandable portion 24. In some embodiments, the reduction in the volume of the distal expandable portion 26 increases the flow of the therapeutic fluid into the bladder volume 48 surrounding the transducer sleeve 22. In some embodiments, the reduction in the volume of the distal expandable portion 26 creates or increases the distance 50 between the distal expandable portion 26 and the bladder wall, which increases the flow of the therapeutic fluid to the volume 48. In some embodiments, the partially expanded proximal expandable portion 24 provides a barrier to the therapeutic fluid flowing into the volume 48.

[0137] Fig. 6E 6 is a simplified plan view illustration of expanding portion 24 to an expanded state by providing fluid into portion 24 via fluid port 14 (e.g., as depicted by arrow 604). In some embodiments, expanding proximal expandable portion 24 to an expanded state by providing fluid via port 14 increases the volume of both proximal and distal expandable portions 24 / 26.

[0138] In some embodiments, the expandable portions 24 / 26 are separate balloons. In some embodiments, during or after the proximal portion 24 is further advanced into the bladder 1, at least a portion of the fluid within the distal expandable portion 26 is removed via the fluid port 15. In some embodiments, the volume of the distal expandable portion 26 is reduced. In some embodiments, during or after the proximal portion 24 is further advanced into the bladder 1, the proximal expandable portion 26 is at least partially expanded by providing fluid via the fluid port 14. In some embodiments, once the therapeutic fluid enters the volume 48 surrounding the transducer sleeve 22, the distal expandable portion 26 is expanded by providing fluid into the distal expandable portion 26 via the fluid port 15.

[0139] In some embodiments, ultrasound driven therapy performed by catheter 10 inserted into bladder 1 is performed by a method according to some embodiments of the present invention and comprises:

[0140] The catheter 10 is secured in the bladder 1 by ensuring that the expanded balloon portion 24 engages the proximal surface 5 of the bladder 1;

[0141] At step 1070, the acoustic fluid is circulated within the transducer portion 22 by providing the acoustic fluid via the first fluid port 15 and extracting the acoustic fluid via the second fluid port 14;

[0142] At step 1080, the transducer 30 is activated; and

[0143] At step 1090, cavitation is formed in the treatment fluid within the bladder treatment volume.

[0144] In some embodiments, according to some embodiments of the present invention, ultrasound driven therapy performed by catheter 10 inserted into bladder 1 is terminated by:

[0145] deactivating the transducer 30;

[0146] extracting therapeutic fluid 17 through therapeutic fluid port(s);

[0147] supplying saline (e.g., to cleanse the bladder) through therapeutic fluid port(s) 17; and

[0148] collapsing the expansion portions 26, 22, 24 by releasing or pumping out the acoustic fluid through one or more of the acoustic fluid ports 14 and 15; and

[0149] The catheter 10 is withdrawn from the bladder 1 via the urethra 3 .

[0150] Reference now Figure 7 , which is a flow chart of a method for deploying a catheter for ultrasound-driven treatment of the bladder wall and treating the bladder according to some embodiments of the present invention. Figure 7 As shown, the method for deploying the catheter 10 in the bladder 1 is performed as follows:

[0151] At step 1400 , a catheter 10 is inserted into the bladder 1 through the urethra 3 ;

[0152] At step 1410 , urine is removed from the bladder 1 via the port(s) 17 ;

[0153] At step 1420, the expandable portions 24, 26 and transducer sleeve 22 are expanded to a predetermined pressure or volume by pressurized acoustic fluid (e.g., 20cc-40cc of fluid), and the expanded portions 24 / 26 and transducer sleeve 22 are maintained in the expanded state; and

[0154] Optionally, at step 1430 , fluid is drained from the bladder through the therapeutic fluid port(s) 17 .

[0155] In some embodiments of the present invention and as Figure 7As further shown, after deploying the catheter is a method of treating the bladder, the method comprising:

[0156] At step 1440, saline is supplied through the therapeutic fluid port(s) 17;

[0157] At step 1450, supplying liquid, optionally aerated as described elsewhere herein, through bladder treatment fluid port(s) 17;

[0158] At step 1460, the transducer 30 is activated;

[0159] At step 1470, deactivate the transducer 30;

[0160] At step 1480, draining the bladder's optionally inflated fluid through the therapeutic fluid port(s) 17;

[0161] At step 1490 , therapeutic fluid (eg, 20-40 cc) is supplied through therapeutic fluid port 17 .

[0162] In some embodiments, the method includes expanding the proximal expandable portion, and capturing a therapeutic fluid between the distal expandable portion and the proximal expandable portion.

[0163] In summary and according to some embodiments of the present invention, treatment of bladder includes at least the following methods:

[0164] Method A, wherein:

[0165] deploying a catheter in the bladder for ultrasound-driven treatment of the bladder wall;

[0166] The therapeutic fluid (e.g. ) is supplied to the bladder;

[0167] formation of cavitation in the fluid within the bladder; and

[0168] Empty the bladder.

[0169] Method B, where:

[0170] deploying a catheter in the bladder for ultrasound-driven treatment of the bladder wall;

[0171] The therapeutic fluid (e.g. ) is supplied to the bladder;

[0172] Cavitation is formed in the fluid within the bladder for a predetermined period of time, and then

[0173] retaining the therapeutic fluid in the bladder for a predetermined period of time; and

[0174] Empty the bladder.

[0175] Method C, where:

[0176] deploying a catheter in the bladder for ultrasound-driven treatment of the bladder wall;

[0177] supplying gaseous fluid to the bladder;

[0178] Cavitation is formed in gaseous fluids;

[0179] exhausting the gaseous fluid; and

[0180] The bladder is supplied with therapeutic fluid.

[0181] Method D, wherein:

[0182] deploying a catheter in the bladder for ultrasound-driven treatment of the bladder wall;

[0183] supplying gaseous therapeutic fluid to the bladder;

[0184] forming cavitation in the gaseous fluid for a predetermined period of time; and then

[0185] Empty the bladder.

[0186] Reference now Fig. 8A and Figure 8B (collectively, FIG. 8 ), which are simplified side and perspective illustrations of a catheter for ultrasound-driven bladder therapeutic agent delivery according to some embodiments of the present invention. As shown in FIG. 8 , catheter 110 includes tube 111, proximal balloon 124 mounted on tube 111, and expandable transducer sleeve 122. Turning to enlarged view B in FIG. 8 , in some embodiments, the diameter of distal portion 111b of tube 111 is smaller than the diameter of proximal portion 111a of tube 111. In some embodiments, as shown in view B in FIG. 8 , portion 111b includes distal tip 117. In some embodiments, portion 111b is connected to tube 111 under the proximal edge of transducer 130. In some embodiments, transducer 130 is mounted on portion 111b of tube 111 so that the outer surface of transducer 130 is positioned flush with proximal portion 111a of tube 111. In some embodiments, portion 111b includes a narrow tube portion inserted into tube 111.

[0187] In some embodiments, transducer 130 is mounted on portion 111b of tube 111 between proximal expandable portion 124 and distal end 117 of the tube. In some embodiments, transducer sleeve 122 houses and encapsulates transducer 130 and enables flow of fluid at an interior volume defined by the walls of transducer sleeve 122. In some embodiments, tube 111 includes one or more treatment fluid ports 116 at proximal portion 111a of tube 111, distal to expandable portions 122 and 124 and exposed to the bladder volume.

[0188] In some embodiments, the proximal balloon 124 can be expanded from a collapsed state to an expanded state. In some embodiments, the expanded state is defined as the maximum inelastic expansion of the balloon. In some embodiments, the expanded state of the balloon is defined as the maximum elastic expansion of the balloon being elastic. Tube 111 includes one or more fluid ports 114, 115a and 115b, which are configured to supply fluid to at least one of expandable portions 122 and 124 or remove fluid from at least one of the expandable portions 122 and 124. Expandable portions 122 and 124 can be expanded via supplying fluid under positive pressure through at least one of fluid ports 114, 115a and 115b. In some embodiments, tube 111 includes one or more fluid supply channels (not shown) inside tube 111 and / or along the outer surface of the tube. In some embodiments, by providing fluid via one of the fluid ports (e.g., port 115a) and removing fluid via another fluid port (e.g., port 115b), a fluid stream is generated in the lumen defined by the wall of the transducer sleeve 122. In some embodiments, the fluid supply port (e.g., port 115a) and the fluid removal port (e.g., port 115b) are disposed on diametrically opposed surfaces of the catheter 110. In some embodiments, the fluid supply port (e.g., port 115a) is located on portion 111b of the tube 111, while the fluid removal port (e.g., port 115b) is disposed on the tube 111. In some embodiments, the fluid supply port (e.g., port 115a) and the fluid removal port (e.g., port 115b) are disposed on opposite sides of the transducer 130. In some embodiments, the fluid supply port (e.g., port 115a) and the fluid removal port (e.g., port 115b) are circumferentially rotated relative to each other.

[0189] In some embodiments, the fluid input into the balloon comprises an acoustic fluid. The acoustic fluid maintains a fixed distance between the surface of the transducer 130 and the transducer sleeve 122. In some embodiments, the acoustic fluid helps cool the enclosed transducer 130, for example, by thermal convection.

[0190] In some embodiments, cooling of the transducers facilitates their operation at desired parameters for longer treatment durations, thereby avoiding overheating of tissue while providing effective treatment. In some embodiments, and as described in more detail elsewhere herein, removing heat from the transducers prevents overheating of bladder tissue, which allows for an increased range of operating parameters, such as longer treatment times and / or an increase in transducer frequency.

[0191] In some embodiments, such as in the treatment of urobladder, the procedure is performed with the bladder positioned vertically or nearly vertically, with the trigone being the lowest part of the urobladder. Fig. 9As shown in the exemplary embodiment depicted in , which is a side view simplified illustration of an embodiment of ultrasound-driven bladder therapeutic agent delivery within the bladder according to some embodiments of the present invention, in an expanded state, a proximal balloon 124 engages the proximal surface of the bladder at the trigone region. The proximal balloon 124 occupies the volume of the bladder 100, thereby forming a treatment volume 107. The balloon 124 in the expanded state prevents fluid from draining from the volume 107 via the balloon wall being pushed against the bladder wall 105. In some embodiments, the balloon 124 is pushed against and seals the proximal surface of the bladder 105' (the trigone region), for example, by static forces (such as gravity or fluid pressure). Therefore, during treatment, the therapeutic fluid is maintained within the volume 107, while the proximal surface of the bladder 105' (the trigone region) located distal to the proximal balloon 124 remains protected from exposure to the therapeutic fluid and acoustic energy. In some embodiments of the present invention, the balloon 124 serves as a catheter base and fixes the position and orientation of the tube 111 relative to the bladder and the elements mounted on the tube within the bladder 100.

[0192] When treatment is not required on the distal region or other areas of the bladder, the treatment fluid may be provided to the bladder in an amount that only fills a portion of the bladder. During treatment, due to gravity, the level of the fluid will be below the predetermined surface and will therefore not be treated by the treatment fluid and the acoustic energy. Fig.10 , which is a side view simplified illustration of an implementation of ultrasound-driven bladder therapeutic agent delivery within the bladder according to some embodiments of the present invention, a therapeutic fluid partially fills a volume 107 of the bladder 100. Because the bladder 100 is oriented vertically, the direction of gravity is indicated by the arrow (G), and the therapeutic fluid is maintained between the fluid levels E1 and E2. During treatment, only the portion of the bladder wall in the region 105" that is distal (above) the proximal balloon 124 and within the volume 107 will receive the therapeutic fluid and acoustic energy.

[0193] In some embodiments, the area of ​​the bladder wall affected by treatment is defined by the dimensions of elements of the catheter 100 , such as the cross-section of the proximal balloon 124 , the distance between the port 116 and the face 124 b , and the distance between the port 116 and the transducer sleeve 122 .

[0194] The transducer sleeve 122 isolates the transducer 130 from the therapeutic agent and prevents cavitation bubbles from forming near or on the transducer surface. Thus, the transducer can be positioned farther away from the inner wall of the bladder than would be the case without the transducer sleeve 122. This allows for distribution of cavitation bubbles within the treatment volume 107 to induce cavitation on the bladder wall, thereby increasing the efficacy of the energy emitted by the transducer to the bladder wall. Some of the parameters that determine the expanded geometry of the transducer sleeve 122 may be: the size and number of transducers 130 it encloses, the flow characteristics of the fluid within its internal volume, the desired volume of the bladder independent of the transducer sleeve, etc. The transducer sleeve 122 may be characterized as being inelastic with a fixed expanded length, being rigid or including a reinforcing element, and in some embodiments, the sleeve may be pressurized to a higher pressure than other expandable portions.

[0195] Go to Fig.11 , which is a simplified side view illustration of a catheter for ultrasound-driven bladder therapeutic agent delivery according to some embodiments of the present invention. Fig.11 As shown in the exemplary embodiment depicted in FIG, during implementation, the geometry of the catheter 150 protects the bladder wall from collapsing onto the transducer sleeve 122. Fig.11 As shown, the bladder wall tends to conform to the geometry of the catheter 10, thereby forming Fig.11 140 is depicted by a dotted triangle 143 in FIG. In some embodiments, the tip 117 of the catheter 150 forms the apex 141 of the cone 140, and the base 142 of the cone 140 is formed at the maximum cross-sectional area of ​​the proximal balloon 124 in the expanded state. In this configuration, the bladder wall is prevented from collapsing onto and contacting the transducer sleeve 122 in the expanded state. For example, this constraint can be driven by requiring that a distance between the transducer sleeve wall and the enclosed transducer be maintained (e.g., in the case where the bladder surface collapses and engages with the sleeve 122) to avoid sleeve bending, etc. In some embodiments, in the expanded state, the diameter D110 of the proximal balloon 124 is between 20 mm and 50 mm. In some embodiments, in the expanded state, the diameter D110 of the proximal balloon 124 is between 30 mm and 38 mm. In some embodiments, the diameter D120 of the transducer sleeve 122 is between 5 mm and 20 mm. In some embodiments, the diameter D120 of the transducer sleeve 122 is between 8 mm and 17 mm. In some embodiments, the diameter D120 of the transducer sleeve 122 is between 12 mm and 14 mm. In some embodiments, in the expanded state, the length L130 of the transducer sleeve is between 5 and 50 mm. In some embodiments, in the expanded state, the length L130 of the transducer sleeve is between 15 and 40 mm.

[0196] In some embodiments, catheter 150 may include two different balloons, such as shown in FIGS. Fig.12 In some embodiments, different pressures or different pressure fluids can be used to expand portions of the proximal balloon 124 and the transducer sleeve 122. In some embodiments, only portions of the wall of the balloon 124 are elastically expandable, while other portions are inelastic.

[0197] In some embodiments, a method for deploying an ultrasound-driven catheter according to some embodiments of the present invention comprises:

[0198] Inserting the catheter 110 into the bladder 100 through the urethra 103 until the distal end 117 engages the distal (opposite the trigone) inner surface 105 of the bladder;

[0199] Expanding the balloon 124 and the transducer sleeve 122 to a predetermined pressure or volume by means of a pressurized acoustic fluid, and maintaining all expanded portions in an expanded state;

[0200] draining the bladder 100 through the therapeutic fluid port(s) 116;

[0201] washing the bladder by inserting saline via port(s) 116 and draining the saline;

[0202] As described elsewhere herein, mixing the therapeutic fluid with the inflation liquid (this step may be optional or performed at any time before or during deployment of the catheter); and

[0203] Therapeutic fluid is provided through therapeutic fluid port(s) 116 .

[0204] In some embodiments, a method for treating a bladder wall using an ultrasound driven catheter according to some embodiments of the present invention comprises:

[0205] The catheter 110 is secured in the bladder 100 by ensuring that the expansion balloon 124 engages the proximal wall of the bladder (the trigone region) 105 ′;

[0206] According to some embodiments of the present invention, the acoustic fluid is circulated within the transducer portion 122 by supplying fluid via the first fluid port 115a and removing the acoustic fluid via the second fluid port 115b; and

[0207] The transducer 130 is activated.

[0208] In some embodiments, according to some embodiments of the present invention, ultrasound driven therapy performed by catheter 110 inserted into bladder 100 is terminated by:

[0209] deactivating the operation of the transducer 130;

[0210] removing therapeutic fluid through therapeutic fluid port 116;

[0211] Saline is inserted through port 116 onto bladder surface 105 (eg, to cleanse the bladder).

[0212] collapsing the expansion portions 124, 122 by releasing or draining the acoustic fluid through the acoustic fluid ports 114, 115a, and 115b; and

[0213] The catheter 110 is withdrawn from the bladder 100 through the urethra 103 .

[0214] According to some embodiments of the present invention, deployment of a catheter for ultrasound driven treatment of the bladder wall and treatment within the bladder is performed by:

[0215] Inserting a catheter 110 into the bladder 100 through the urethra 103;

[0216] Expanding the balloon 124 and the transducer sleeve 122 to a predetermined pressure or volume by pressurizing the acoustic fluid (e.g., 20cc-40cc of fluid), and maintaining the expanded balloon 124 and the transducer sleeve 122 in the expanded state;

[0217] draining fluid from the bladder via therapeutic fluid port(s) 116;

[0218] supplying saline via therapeutic fluid port(s) 116;

[0219] supplying an aerated fluid as described elsewhere herein through bladder treatment fluid port(s) 116;

[0220] activating the transducer 130;

[0221] deactivating the transducer 130;

[0222] draining the inflation fluid of the bladder 100 through the therapeutic fluid port(s) 116;

[0223] Therapeutic fluid (eg, 20-40 cc) is supplied through the therapeutic fluid port(s) 116 .

[0224] In some embodiments of the catheter for ultrasound-driven treatment of the bladder, at least one of the expandable portions in the expanded state is shaped as at least one of a sphere, an ellipsoid, or a toroid. In some embodiments, at least one of the expandable portions in the expanded state comprises a C-shaped cross-section. In some embodiments, at least one of the expandable portions in the expanded state comprises an umbrella-like configuration.

[0225] For example, Fig.12An embodiment is shown in which the geometry of the expandable portion 824 is annular. In some embodiments, the catheter 811 includes a treatment fluid port 816 between the transducer sleeve 822 and the expandable portion 824. Fig.12 In the exemplary embodiment shown, as indicated by arrow 850, the annular expandable portion 824 expands distally along the catheter 811 toward the tip 802 when expanded and directs any therapeutic fluid supplied via the therapeutic fluid port 816 into the treatment volume 807 to surround the transducer 830, thereby increasing the therapeutic efficacy.

[0226] Potential advantages of this configuration are that the treatment area is more limited and therefore more accurately defined, and that a smaller amount of treatment fluid is required to treat a given area of ​​the bladder wall, thereby limiting waste of treatment fluid.

[0227] The shaping of any balloon may be accomplished by molding, thickness differences, varying materials, integral components, etc. Another method for shaping any balloon portion may be to limit its expansion by an external component such as a sleeve or mesh.

[0228] In some embodiments, the catheter for ultrasound-driven treatment of the bladder is configured as an energy supply catheter including an ultrasonic transducer 30 / 130 / 830. In addition, in some embodiments, the catheter for ultrasound-driven treatment of the bladder includes one or more thermocouples disposed in one or more expandable portions. In some embodiments, the thermocouple is configured to measure the temperature of the fluid in the treatment volume. In some embodiments, one or more thermocouples are configured to measure the temperature of the bladder wall tissue to prevent overheating of the bladder wall. In some embodiments, one or more thermocouples are coupled to the bladder wall. In some embodiments, the thermocouple is configured to measure the temperature of the fluid in one or more expandable portions and / or the transducer sleeve. In some embodiments, the thermocouple is configured to measure the temperature above the transducer surface. In some embodiments, the catheter for ultrasound-driven treatment of the bladder includes one or more pressure sensors configured to monitor the fluid pressure in the expandable portion in at least one expandable portion. In the exemplary embodiments shown in Figures 1 and 4, the transducer 30 / 130 is cylindrical. However, in other embodiments, the transducer may be flat. In some embodiments, the transducer 30 / 130 is mounted on the tube 11 / 111 via spacers 32 / 132 and 33 / 133. The fixation of the transducer at a predetermined position on the tube provides predictable and repeatable energy parameters.

[0229] In some embodiments, the spacers 32 / 132 and 33 / 133 are configured to support the transducer elevated from the tube 11 / 111 so as to form a gap between the transducer and the tube 11 / 111. In some embodiments, the gap is in a range between 0.05 mm and 4 mm. In some embodiments, the gap is in a range between 0.1 mm and 2.5 mm. In some embodiments, the gap is filled with an acoustic fluid flowing within the enclosed transducer sleeve 22 / 122, which results in cooling of the transducer. In some embodiments, the gap is filled with an acoustic fluid flowing in the transducer sleeve 22 / 122, thereby transferring heat away from the transducer.

[0230] In some embodiments, one or more of the spacers 32 / 33 / 132 / 133 are mounted on the tube 11 / 111. In some embodiments, the transducer 30 / 130 is mounted on one or more of the spacers 32 / 33 / 132 / 133. In some embodiments, the transducer 30 / 130 is positioned on one spacer 32 / 33 / 132 / 133. In some embodiments, the transducer 30 / 130 is positioned on a plurality of spacers 32 / 33 / 132 / 133. In some embodiments, the length of the spacer 32 / 33 / 132 / 133 is greater than the outermost radius of the spacer 32 / 33 / 132 / 133. In some embodiments, the length of the spacer is at least 50% of the length of the transducer 30 / 130. In some embodiments, the length of the spacer 32 / 33 / 132 / 133 is at most 30% of the length of the transducer 30 / 130.

[0231] In some embodiments, the spacer 32 / 33 / 132 / 133 adds concentricity, electrical protection, and mechanical support to a catheter for ultrasound-driven bladder drug delivery. In some embodiments, the transducer is kept at a distance from the catheter and / or tube, providing electrical insulation by having an isolation medium (e.g., air) between the transducer and the catheter.

[0232] Go to Fig.13 and Fig.14 , which are simplified illustrations of side views of catheters for ultrasound-driven bladder drug delivery according to some embodiments of the present disclosure. Fig.13 and 14As shown, the normally open stent (e.g., expandable stent 224, 324, 326) replaces at least some of the expandable portions (such as 24, 26, 124) disclosed in the previous embodiments, which can be replaced by the normally open stent (e.g., expandable stent 224, 324, 326). Each of the stents 224, 324, 326 is configured to be normally open and remain enclosed in a stent sleeve (not shown) before the catheter 210 / 310 is inserted into the bladder. The stent is configured to open and engage the bladder wall when exposed from the stent sleeve. Any stent may have a fluid sealing surface to block the fluid in the bladder cavity volume defined in the bladder on one side of the sealing surface so as to flow into the bladder cavity volume defined on the opposite side of the stent sealing surface.

[0233] In the embodiments shown in Figures 1 and 8, the transducer is fixed to the tube by a spacer (e.g., 32 / 132 and 33 / 133). The fixation of the transducer at a predetermined position and the concentration around the tube help provide predictable and repeatable energy parameters. The spacer supports the transducer so that a gap is defined between the transducer and the tube. In some embodiments, the gap is in the range of 0.05 to 4 mm. In some embodiments, the gap is in the range of 0.1 to 2.5 mm. In some embodiments, the gap is filled with an acoustic fluid flowing in a closed transducer sleeve 22 / 122 / 222 / 322822, thereby cooling the transducer.

[0234] In some embodiments, at least one of the stents 224, 324, 326 may be replaced by a balloon. In some embodiments, a catheter for ultrasound driven bladder drug delivery comprises at least one balloon, at least one stent, or any combination thereof.

[0235] According to some embodiments of the present invention, the following are some examples of treatment parameters that enable effective and safe treatment:

[0236] In some embodiments, the ultrasonic transducer is between 100-400Khz. In some embodiments, the ultrasonic transducer is between 125-350Khz. In some embodiments, the ultrasonic transducer is between 150-300Khz.

[0237] In some embodiments, the ultrasonic transducer duty cycle is between 5-50%. In some embodiments, the ultrasonic transducer duty cycle is between 7-45%. In some embodiments, the ultrasonic transducer duty cycle is between 10-40%.

[0238] In some embodiments, the ultrasonic Isppa intensity is between 5-60W / cm2. In some embodiments, the ultrasonic Isppa intensity is between 8-55W / cm2. In some embodiments, the ultrasonic Isppa intensity is between 10-50W / cm2.

[0239] The distance between the bladder and the ultrasound transducer ranges from 1 to 30 mm.

[0240] In some embodiments, the total treatment time using the transducer ranges from 5-30 minutes. In some embodiments, the total treatment time using the transducer ranges from 10-25 minutes. In some embodiments, the total treatment time using the transducer ranges from 15-20 minutes.

[0241] In some embodiments, the acoustic fluid pressure ranges from 0.3 MPa to 2 MPa. In some embodiments, the acoustic fluid pressure ranges from 0.5 MPa to 1 MPa.

[0242] In some embodiments, 3-40 mL of fluid fills the volume of the transducer sleeve. In some embodiments, 5-20 mL of fluid fills the volume of the transducer sleeve. In some embodiments, 10-14 mL of fluid fills the volume of the transducer sleeve.

[0243] In some embodiments, 3-100 mL of fluid fills the volume of at least one expandable portion 24 / 26 / 124 / 824. In some embodiments, 10-70 mL of fluid fills the volume of at least one expandable portion 24 / 26 / 124 / 824. In some embodiments, 30-55 mL of fluid fills the volume of at least one expandable portion 24 / 26 / 124 / 824.

[0244] In some embodiments, 5-300 mL of fluid flows into the bladder volume. In some embodiments, 15-100 mL of fluid flows into the bladder volume. In some embodiments, 25-50 mL of fluid flows into the bladder volume.

[0245] The bubbles in the liquid act as nucleation seeds for generating cavitation. Therefore, increasing the amount of bubbles in the treatment fluid increases the efficacy of the ultrasound treatment.

[0246] In addition, ultrasound transducers introduced into the bladder are generally limited in the energy level they emit. In addition, the fluid medium partially blocks and / or slows down the ultrasound waves traveling from the transducer toward the bladder wall, thereby exposing the bladder wall to energy that may be insufficient to drive the therapeutic agent onto the tissue. Therefore, in order to effectively treat the bladder wall, the ultrasound transducer needs to be activated in close proximity to the bladder wall, which increases the risk of damaging the wall tissue due to exposure to excessive heat generated from the transducer.

[0247] Introducing nucleation seeds (such as solid particles, semi-solids, microbubbles, etc.) in the treatment fluid distributes the bubbles throughout the fluid. The bubbles near the transducer absorb part of the ultrasound radiation by forming cavitation, however, the presence of the bubbles throughout the treatment volume and especially near the bladder wall enables its activation (i.e., the generation of cavitation) even by low energy ultrasound waves that would be ineffective without the nucleation seeds. The dispersion of cavitation in the treatment fluid allows cavitation to be spread throughout the treatment fluid, not just in the layer encountered by the ultrasound transmission wave in the direct vicinity of the transducer sleeve.

[0248] Therefore, the presence of these bubbles reduces the energy threshold required for cavitation generation. This allows the use of less acoustic energy, making the treatment safer for the tissue. In some embodiments, the amount of cavitation bubbles in the treatment fluid liquid is increased by adding an aerated sterile liquid (such as saline) to the treatment agent.

[0249] In some embodiments of the present invention, there is provided a method for increasing the amount of cavitation bubbles within a therapeutic fluid liquid, comprising:

[0250] - pressurizing a sterile liquid with a gas to produce an aerated liquid;

[0251] -Maintaining the inflation liquid compression for a predetermined duration;

[0252] - The therapeutic fluid is prepared by releasing the therapeutic agent (in powder or liquid form) into the aerated liquid.

[0253] For example, in some embodiments, the gas is at least one of air, helium, nitrogen, oxygen, or any combination thereof. In some embodiments, the pressure at which the sterile liquid is pressurized with the gas is 8 to 30 atmospheres. In some embodiments, the predetermined duration is between 0.5 and 2 hours. In some embodiments, the predetermined duration is 1 hour.

[0254] When an aerated liquid is added to the treatment fluid, the balance of gases tilts towards the treatment agent, thereby increasing the gas content therein. When it is decompressed within the treatment agent (due to the immediate release of pressure), the balance of gases tilts towards the surrounding atmosphere and the excess gas is released in the form of small bubbles. These small bubbles act as cavitation nucleation sites during treatment.

[0255] In some embodiments, the therapeutic fluid is mixed into the inflation fluid. In some embodiments, the inflation fluid is mixed into the therapeutic fluid. In some embodiments, the inflation fluid is a diluent for the therapeutic fluid.

[0256] Example 1

[0257] The following experiments were performed to determine the difference between untreated tissue and the gold standard 100 units Therapeutic efficacy of intravesical injection compared with a catheter for ultrasound-driven treatment of the bladder.

[0258] refer to Fig.15 , which is an exemplary graph of parameters of an implementation of a catheter for ultrasound-driven treatment of the bladder according to some embodiments of the present invention. The following experiment was tested on 8 pigs.

[0259] In this embodiment, the catheter for ultrasound-driven treatment of the bladder is started by applying local anesthesia to the bladder 1. Next, at step 1400, the catheter 10 is inserted into the bladder 1 through the urethra 3, and at step 1420, the expandable portion 24, 26 and the transducer sleeve 22 are expanded by filling 10-15 mL. In this example, the bladder 1 is washed twice with saline by supplying saline at step 1440 and then draining the bladder 1 through the treatment fluid port (one or more) 17 at step 1430.

[0260] Next, 30 mL of treatment fluid was then instilled into the bladder, and the expandable portions 24, 26 and transducer sleeve 22 were fully inflated to 35 mL within the bladder. A pump was started to circulate the acoustic fluid within the expandable portions 24, 26 and transducer sleeve 22. The transducer was turned on at a frequency of 200 kHz for 15 minutes and then turned off, as shown in FIG. Fig.15 The duty cycle of the transducer was 15%. Finally, the treatment fluid was incubated for 10 minutes in the post-bladder treatment. Fig.15 Depicted.

[0261] In this example, the therapeutic agent is botulinum toxin A Solution in saline. The dose of toxin is 100-200 units. In this example, the saline is plain sterile saline. In some embodiments, and in this example, the fluid is not aerated.

[0262] In addition, use the gold standard 100 units Three pigs were treated with intravesical injection.

[0263] Pathology reports were obtained for the bladder, kidneys, urethra, ureters, and other organs. In addition, the therapeutic efficacy of the catheter used for ultrasound-driven treatment of the bladder was compared with the gold standard 100-unit injections and were compared with a control group of pigs that did not receive any treatment, as measured by measuring the contractility of the detrusor muscle after each treatment.

[0264] refer to Fig.16 , which is a graph of detrusor contractility after each treatment (treatment using a catheter for ultrasound-driven treatment of the bladder) compared to untreated tissue, and the gold standard 100 units Graph comparing detrusor contractility after intravesical injection. The detrusor contractility after each treatment shown on the y axis is the percentage of the contractility after treatment relative to the detrusor contractility after receiving carbachol (CCh). The ratio of contractility to CCh depicts the amount of each detrusor contraction relative to the maximum contraction obtained by CCh treatment.

[0265] exist Fig.16 In the graph, the shrinkage is 100% with CCh and no activity, while lower percentages of muscle activity were consistent with The results showed that the use of catheters for ultrasound-driven therapy was comparable to the gold standard 100 units Intravesical injections all achieved better results than untreated controls, however, treatment efficacy using a catheter for ultrasound-driven therapy was at least equal to or greater than the gold standard intravesical injection treatment.

[0266] For example, at a frequency of 8 Hz, the ratio of contractility to CCh of bladders receiving treatment using the catheter was approximately 39%, while the ratio of contractility to CCh of bladders receiving intravesical injection was approximately 44%, and the control group was at approximately 61%.

[0267] At a frequency of 32 Hz, the ratio of contractility to CCh of the bladder receiving treatment using the catheter was about 78%, while the ratio of contractility to CCh of the bladder receiving the intravesical injection was about 82%, and the control group was at 100%.

[0268] Example 2

[0269] The following experiment was conducted to determine the therapeutic efficacy of using a catheter for ultrasound-driven treatment of overactive bladder (OAB) in human patients. The parameters of an embodiment of the catheter for ultrasound-driven treatment correspond to Fig.16 The treatment parameters for the pigs are shown in the depicted table and in Example 1. Ten individuals were treated and observed for 14 days post-surgery.

[0270] The results of human bladder treatment using a catheter for ultrasound-driven therapy showed no serious or minor adverse events. In addition, specific data on bladder function were obtained from two patients before and after the procedure.

[0271] People with overactive bladder experience sudden and frequent urges to urinate during the day and night due to involuntary contractions of the detrusor muscle.

[0272] refer to Fig.17 , which is a table of efficacy data from two human patients comparing preoperative bladder function to bladder function 14 days postoperatively. Fig.17As shown, the average volume per urination increased by 22% and 27% for patients 3002 and 3004, respectively. The increase in volume per urination indicates that more urine fills the patient's bladder before urination. In addition, the average number of urinations per night for patients 3002 and 3004 decreased by 60% and 10%, respectively, which corresponds to the increase in volume per urination. The increase in volume per urination reduces the number of times the patient needs to urinate.

[0273] like Fig.17 As shown, the mean number of incontinence episodes for patient 3004 was reduced by 62.5%. The mean number of incontinence episodes for patient 3002 did not change. The reduction in the number of incontinence episodes demonstrates the therapeutic efficacy of using a catheter for ultrasound-driven therapy in humans with OAB.

[0274] Finally, post-operative OAB-q (14 days post-operatively) was compared to pre-operative OAB-q for patients 3002 and 3004, showing a decrease of 4.1% and 38.6%, respectively. A decrease in OAB-q scores indicates an increase in overall well-being and a decrease in severity of OAB symptoms.

[0275] Throughout the application, various embodiments of the present invention may be presented in a certain range format. It should be understood that the description in range format is only for convenience and brevity, and should not be interpreted as an inflexible limitation on the scope of the present invention. Therefore, the description of the range should be regarded as having clearly disclosed all possible sub-ranges and each numerical value within the range. For example, the description of the range from 1 to 6 should be regarded as having clearly disclosed sub-ranges from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., and single numbers within the range, such as 1, 2, 3, 4, 5 and 6. This applies regardless of the breadth of the range.

[0276] Whenever a numerical range is indicated herein, it is intended to include any cited numeral (fractional or integer) within the indicated range. The phrases "range / ranges between a first indicated numeral and a second indicated numeral" and "range / ranges from" a first indicated numeral "to" a second indicated numeral" are used interchangeably herein and are intended to include the first indicated numeral and the second indicated numeral and all fractions and integers therebetween.

[0277] In the specification and claims of the present application, each of the words "include," "comprises," and "has," and forms thereof, are not necessarily limited to the members of the list with which the words may be associated. Furthermore, in the event of an inconsistency between the present application and any document incorporated by reference, the present application shall control.

[0278] Descriptions of various embodiments of the present invention have been given for purposes of illustration, but these descriptions are not exhaustive and are not limited to the disclosed embodiments. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The terms used herein are selected to best explain the principles of the embodiments, practical applications or technical improvements to technologies found on the market, or to enable other persons of ordinary skill in the art to understand the embodiments disclosed herein.

Claims

1. A catheter for ultrasound-driven delivery of a bladder therapeutic agent, comprising a tube having: one or more expandable portions, the one or more expandable portions being expandable via the one or more first ports, wherein at least one of the one or more expandable portions is a proximal expandable portion; at least one expandable transducer sleeve housing at least one ultrasonic transducer mounted on the tube between the proximal expandable portion and the distal end of the tube, wherein the at least one expandable transducer sleeve is expandable via the one or more first ports; a blind tip at said distal end; one or more second ports positioned along a circumference of the blind tip; as well as a surface positioned distally relative to the second port, wherein the one or more second ports are adapted to perform at least one of: inserting a therapeutic fluid into the lumen of the bladder, inserting a tissue cleaning fluid into the lumen of the bladder, and removing a fluid from the lumen of the bladder, The at least one expandable portion is capable of expanding within the bladder from a contracted state to an expanded state, wherein the expandable portion is urged against a wall of the bladder to form a sealed volume within the bladder between the expandable portion and a trigone region of the bladder.

2. The catheter according to claim 1, comprising at least one additional expandable portion, wherein the at least one expandable transducer sleeve is disposed between the proximal expandable portion and the at least one additional expandable portion.

3. The catheter of claim 1, wherein at least one of the one or more expandable sections is in fluid communication with the at least one expandable transducer sleeve.

4. The catheter of claim 1, wherein the maximum cross-sectional area of ​​the at least one expandable transducer sleeve in an expanded state is less than the maximum cross-sectional area of ​​any of the one or more expandable portions at its maximum circumference.

5. The catheter of claim 1, wherein at least one of the one or more expandable sections and the tube are concentric.

6. The catheter of claim 1, wherein at least one of the one or more expandable sections and the at least one ultrasonic transducer are concentric.

7. The catheter of claim 1, wherein the tube comprises at least one of the one or more first ports located within a lumen of at least one of the one or more expandable portions.

8. The catheter of claim 1, wherein the tube comprises at least two of the one or more first ports in fluid communication with the lumen of the transducer sleeve, and wherein fluid flow is maintained between the at least two ports.

9. The catheter of claim 8, wherein the at least one ultrasound transducer is positioned between the at least two ports.

10. The catheter of claim 1, wherein the tube comprises at least one third port along its length, the at least one third port opening into the lumen of the bladder, wherein the at least one third port is adapted to perform at least one of: inserting a therapeutic fluid into the bladder, inserting a tissue cleaning fluid into the bladder, and removing fluid from the bladder.

11. The catheter of claim 10, further comprising a blind tip at the distal end, wherein at least one of the second ports is located along a circumference of the tip.

12. The catheter of claim 1, wherein the at least one ultrasonic transducer is elevated from a surface of the tube so as to define a gap between the transducer and the surface of the tube.

13. The catheter of claim 1, further comprising at least one spacer positioned on the tube, and wherein the at least one ultrasonic transducer is mounted on the at least one spacer.

14. The catheter of claim 1, wherein the maximum circumference of the transducer sleeve is less than 50% of the maximum circumference of the at least one expandable portion.

15. The catheter of claim 10, wherein the tube comprises one or more conduits that supply fluid via the at least one second port and at least one third port.

16. The catheter of claim 1, wherein at least one of the one or more expandable sections is annular.

17. The catheter of Claim 1, wherein at least one of the one or more expandable portions is configured to expand distally toward the distal end.

18. The catheter of claim 1, further comprising at least one of the one or more first ports being located between at least one of the one or more expandable sections and the at least one ultrasonic transducer.

19. The catheter of Claim 4, wherein in the expanded state, a volume is defined between the at least one ultrasonic transducer and the transducer sleeve.

20. The catheter of claim 1, wherein the therapeutic fluid is a gaseous therapeutic fluid.

21. The catheter of Claim 1, wherein the at least one expandable transducer sleeve comprises a degassed acoustic fluid configured to allow acoustic waves to propagate from the at least one ultrasonic transducer to the transducer sleeve without generating cavitation.

22. The catheter of claim 1, wherein: The one or more second ports include a plurality of second ports.

23. The catheter according to claim 21 further includes one or more pressure sensors configured to monitor fluid pressure within the expandable portion, and wherein at least one of the following is capable of expanding by pressurizing the degassed acoustic fluid to a predetermined pressure: (i) the one or more expandable portions and (ii) the at least one expandable transducer sleeve.

24. The catheter of claim 21, further comprising a thermocouple device configured to monitor the fluid temperature within at least one of: (i) the one or more expandable portions and (ii) the at least one expandable transducer sleeve, and wherein a flow of degassed acoustic fluid is maintained between the at least two fluid ports to cool the transducer by thermal convection.

25. A catheter according to claim 21, wherein the one or more first fluid ports include a fluid supply port (115A) and a fluid removal port (115B) connected to the inner fluid of the transducer sleeve, and wherein the transducer is positioned between the fluid supply port (115A) and the fluid removal port (115B), and wherein a flow of degassed acoustic fluid is maintained between the ports to cool the transducer by thermal convection.

26. The catheter of claim 25, wherein: The fluid supply port and the fluid removal port rotate circumferentially relative to each other.